ACE2 and adenocarcinoma: In vitro evaluation of the activity of (bovine/human) LF against the virulent SARS-CoV-2 using several cell-lines (Vero E6, Caco-2, adenocarcinoma human alveolar basal epithelial cells, A549, Huh7, HEK293T cell expressing ACE2 (293T-ACE2), HCT-8, Calu-3, and MRC-5 cell lines) clearly showed that LF is capable of inhibition of viral activity, in a dose-dependent manner, via the three aforementioned strategies (Campione et al., 2020b; De Carvalho et al., 2020; Fan et al., 2020; Mirabelli et al., 2020).